Management of HIV/AIDS

Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral

Retrieved on: 
Tuesday, June 8, 2021

The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.

Key Points: 
  • The research findings, published in Nature Communications, detailed additional mechanistic, drug product stability, pharmacokinetic, and toxicology studies supporting XVIR-110s profile as a potential best-in-class once-yearly antiretroviral agent.
  • Integrase inhibitors, in addition to capsid inhibitors and nucleoside reverse transcriptase inhibitors, are a class of agents under investigation as long-acting antiretroviral therapies.
  • Preclinical pharmacokinetic and toxicology studies conducted to date support the development of XVIR-110 as a potential once-yearly antiretroviral therapeutic for HIV treatment and prevention.
  • Exavir Therapeutics is a preclinical stage biotechnology company dedicated to eliminating HIV and other viral infections with a broad modality-agnostic approach, beginning with long-acting antiretroviral therapeutics.

Global HIV Pre-Exposure Prophylaxis (HIV PrEP) Disease Analysis Report 2021: Uptake of PrEP is Expected to Continue Following Positive European Reimbursement Decisions - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021

The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HIV Pre-Exposure Prophylaxis (HIV PrEP)" report has been added to ResearchAndMarkets.com's offering.
  • However, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as Gilead's marketing efforts.
  • Within the EU and UK, Truvada is the only approved agent for PrEP but generates minimal sales due to generic competition since July 2017.
  • There are currently six agents in clinical development for pharmacological PrEP, comprising five antiretrovirals and a single broadly neutralizing antibody.

World HIV Treatment Forecast and Market Analysis Report 2021-2027: Market will be Driven by Patients Switching Over from Gilead's Dlder STRs - Genvoya, Stribild, Atripla, Complera, Odefsey - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021

The "HIV Treatment Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HIV Treatment Forecast and Market Analysis to 2027" report has been added to ResearchAndMarkets.com's offering.
  • ViiV Healthcare has maintained its second-place position in the HIV treatment market and is likely to grow its revenues due to new INSTI-based drug launches.
  • HIV/AIDS drugs, on average, take 8.9 years from Phase I to approval, which is in line with the overall infectious disease space.
  • There are three new drugs in late-phase development for the treatment of heavily treatment-experienced patients, namely lenacapavir (capsid inhibitor), islatravir/doravirine (reverse transcriptase translocation inhibitor), and Vyrologix (CCR5 inhibitor).

CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19

Retrieved on: 
Tuesday, June 1, 2021

Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.

Key Points: 
  • Philippine Airlines (PAL) has stepped up to help with one of the main challenges, the long delivery time from the USA to the Philippines.
  • Filipinos can get more information on how to access leronlimab in the Philippines by contacting CytoDyns local distribution partner Chiral Pharma Corporation.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • Leronlimab does not work on other strains of HIV (for example X4), however R5 is the most dominant strain of HIV.

CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines

Retrieved on: 
Tuesday, June 1, 2021

The Company expects to recognize revenues related to this purchase order upon fulfillment of the purchase order and the terms of the agreement.

Key Points: 
  • The Company expects to recognize revenues related to this purchase order upon fulfillment of the purchase order and the terms of the agreement.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • There have been no strong safety signals identified in patients administered leronlimab in multiple disease spectrums, including patients with HIV, COVID-19 and oncology.
  • CytoDyn also completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.

CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines

Retrieved on: 
Tuesday, May 18, 2021

We are very excited for the opportunity to receive our first approval in multiple countries in great need of leronlimab.

Key Points: 
  • We are very excited for the opportunity to receive our first approval in multiple countries in great need of leronlimab.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • This trial will evaluate the effect of leronlimab on clinical symptoms and laboratory biomarkers to further understand the pathophysiology of PASC.
  • CytoDyn has already completed two trial in COVID-19 patients (a Phase 2 and a Phase 3).

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

Retrieved on: 
Wednesday, May 12, 2021

Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.

Key Points: 
  • Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.
  • The NK and GDT cells were collected from a person who does not have HIV.
  • This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time.
  • There is no assurance the findings will result in an effective alternative treatment for HIV.

Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

Retrieved on: 
Wednesday, May 12, 2021

Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.

Key Points: 
  • Presentation can be found at https://www.enochianbio.com/about-us/collaborations/\nA 54-year-old man, diagnosed with HIV in 1986, had persistent HIV detected in his blood, despite antiretroviral therapy.
  • The NK and GDT cells were collected from a person who does not have HIV.
  • This could potentially allow persons living with HIV to stop antiviral treatment for extended periods of time.
  • There is no assurance the findings will result in an effective alternative treatment for HIV.

etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users

Retrieved on: 
Tuesday, May 4, 2021

b'GAINESVILLE, Fla. & BOSTON, May 4, 2021 /PRNewswire/ -- Digital health company, etectRx , Inc., today announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV.

Key Points: 
  • b'GAINESVILLE, Fla. & BOSTON, May 4, 2021 /PRNewswire/ -- Digital health company, etectRx , Inc., today announced the launch of a study to monitor antiretroviral therapy adherence among prescription opioid users living with HIV.
  • The study, dubbed "MyTPill," will assess patient adherence using two electronic adherence tracking technologies: the ID-Cap System from etectRx and an electronic pill box.
  • The FDA-cleared ID-Cap System uniquely addresses the issue with patient adherence to (oral) medication.
  • The accurate, flexible and elegant digital pill system allows pharmaceutical companies to rethink approaches to medication adherence, innovate with confidence, and accelerate patient outcomes.

Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines

Retrieved on: 
Monday, April 19, 2021

Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular hospital room soon.

Key Points: 
  • Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular hospital room soon.
  • CytoDyn is grateful for the opportunity to help the former President and his family and we wish him a full and speedy recovery.
  • The first indication is combination therapy with HAART for HIV-infected patients, and the second is for metastatic triple-negative breast cancer (mTNBC).
  • Nine clinical trials have demonstrated leronlimab could significantly reduce or control HIV viral load in humans.